Case report

Endobronchial aspergilloma: A case report

Aysel Sunnetcioglu a, *, Selami Ekin a, Remzi Erten b, Mehmet Parlak c, Ramazan Esen d

a Yuzuncu Yil University Faculty of Medicine, Department of Chest Diseases, Van, Turkey
b Yuzuncu Yil University Faculty of Medicine, Department of Pathology, Van, Turkey
c Yuzuncu Yil University Faculty of Medicine, Department of Medical Microbiology, Van, Turkey
d Yuzuncu Yil University Faculty of Medicine, Department of Internal Medicine, Van, Turkey

A 28-year-old male with B-cell acute lymphoblastic leukemia presented to our pulmonary clinic with progressive dyspnea, cough, hemoptysis, and fever. Diagnostic bronchoscopy revealed white masses at the entrance of the right middle lobe bronchus and distal to the right main bronchus. Histopathological examination of the biopsy specimen showed those masses to be hyphae of Aspergillus.

1. Introduction

Aspergillus spp. can cause a variety of pulmonary diseases, depending on the immune status of the individual and the presence of underlying lung disease. Pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, chronic necrotizing pulmonary aspergillosis, and invasive aspergillosis are the most common clinical presentations of pulmonary infections due to Aspergillus species [1–4]. Endobronchial aspergillosis is an unusual presentation of pulmonary aspergillosis [5] and is characterized by the growth of Aspergillus species into the bronchial lumen. Endobronchial aspergillosis can mimic endobronchial tumors in terms of the clinical and radiographic presentation. Here, the study describes a case of endobronchial aspergillosis in a patient with B-cell acute lymphoblastic leukemia.

2. Case report

A 28-year-old male previously diagnosed with relapsed B-cell acute lymphoblastic leukemia presented to our pulmonary clinic with progressive dyspnea, cough, hemoptysis and fever. Auscultation revealed bilateral ronchi. On admission, the complete blood count results were normal: white blood cells, 5,000/mm³ (41.7% neutrophils, 49.0% lymphocytes, and 0.1% eosinophils); hemoglobin, 8.5 g/dL; and platelets, 18,000/mm³ after chemotherapy. The C-reactive protein level was 57 mg/IU. Bilateral multiple opacities were detected on the chest X-ray (Fig. 1). Computed tomography revealed multiple areas of consolidation distributed randomly throughout the lung (Fig. 2). Bronchoscopy was performed for evaluate the cause of hemoptysis and to diagnose lung parenchymal lesions. Diagnostic flexible bronchoscopy revealed that, distal to the right main bronchus, the right lung middle lobe bronchial entrances were narrowed by a white mass (Fig. 3). A biopsy was obtained from the white mass at the entrance of the middle lobe bronchus. Microscopy of the biopsy samples showed fungal hyphae that stained with Periyodik Asit Shift(PAS) (Fig. 4), and Aspergillus fumigatus was grown in culture. The patient was diagnosed as aspergillosis and voriconazole was started.

3. Discussion

Endobronchial aspergillosis is a rare presentation of pulmonary aspergillosis. It can present as a noninvasive form of aspergillosis characterized by growth of Aspergillus spp. within the bronchi, with or without parenchymal lesions or cavities. Aspergillus airway infection can complicate the course of various malignant diseases, the risk being highest in severely immunocompromised patients with hematological malignancies. The clinical presentation of aspergillosis is quite diverse. Many patients are asymptomatic, although some present with symptoms such as cough, dyspnea, hypoxia, hemoptysis and weight loss. The
Fig. 1. Chest radiogram demonstrating multiple opacities.

Fig. 2. Thorax computed tomogram showing consolidated areas in the lung distributed randomly.

Fig. 3. The bronchoscopy shows a whitish mass lesion causing partially obstruction of distal the right main bronchus (A), and complete obstruction of entrance the middle lobe bronchus (B).

Fig. 4. The histologic examination shows numerous hyphae with background necrotic debris hematoxylin and eosin. ×400(A), Peryodik Asit Shift(PAS) (B).
potential for endobronchial aspergillosis to progress rapidly to respiratory failure has previously been reported [6,7]. In addition, the need for mechanical ventilation drastically affects mortality rates, which have been reported to be 94% for endobronchial aspergillosis patients on mechanical ventilation, compared with 25% for those not requiring mechanical ventilation [8].

In many cases, endobronchial aspergilloma is incidentally detected in patients who have undergone bronchoscopy to evaluate the cause of hemoptysis and to diagnose parenchymal lung lesions [5]. Bronchoscopic findings vary from yellowish-white necrotic plaques to whitish nodules.

Since the most reliable criterion of fungal airway disease is demonstration of tissue invasion and damage caused by hyphae [9–11], bronchoscopy with biopsy, microscopy, and culture is the only way to confirm invasive Aspergillus tracheobronchial infection in the clinical setting [12].

The optimal treatment or duration of therapy for endobronchial aspergilloma has yet to be established since this unique presentation of Aspergillus seen in immunocompetent indivi-duals are usually diagnosed incidentally. Treatment options include amphotericin B, voriconazole, itraconazole, and caspofungin.

Finally, although endobronchial aspergilloma is extremely rare, it should be considered in the differential diagnosis of endobronchial masses in immunocompromised patients.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

References

[1] A.O. Soubani, P.H. Chandrasekar, The clinical spectrum of pulmonary aspergillosis, Chest 121 (2002) 1988–1999.
[2] O.S. Zmeili, A.O. Soubani, Pulmonary aspergillosis: a clinical update, QJM 100 (2007) 317–334.
[3] T. Franquet, N.I. Müller, A. Giménez, P. Guembe, J. de La Torre, S. Bagué, Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic find-ings, Radiographics 21 (2001) 825–837.
[4] D.L. Klein, G. Gamsu, Thoracic manifestations of aspergillosis, AJR Am. J. Roentgenol. 134 (1980) 543–552.
[5] J.E. Ma, E.Y. Yun, Y.E. Kim, et al., Endobronchial aspergilloma: report of 10 cases and literature review, Yonsei Med. J. 52 (2011) 787–792.
[6] C. Routsi, P. Kaltsas, E. Bessis, D. Rontogianni, S. Kollias, C. Roussos, Airway obstruction and acute respiratory failure due to Aspergillus tracheobronchitis, Crit. Care Med. 32 (2004) 580–582.
[7] C. Routsi, E. Platsouka, A. Prekates, D. Rontogianni, O. Paniara, C. Roussos, Aspergillus bronchitis causing atelectasis and acute respiratory failure in an immunocompromised patient, Infection 29 (2001) 243–244.
[8] S. Tasci, A. Glassmacher, S. Lentin, K. Tschuvel, S. Eweig, E. Molitor, et al., Pseudomembranous and obstructive Aspergillus tracheobronchitis—optimal diagnostic strategy and outcome, Mycoses 49 (2006) 37–42.
[9] D.W. Denning, Commentary: unusual manifestations of aspergillosis, Thorax 50 (1995) 812–813.
[10] S. Ascioglu, J.H. Rex, B. de Pauw, J.E. Bennett, J. Bille, F. Crokaert, et al., Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus, Clin. Infect. Dis. 34 (2002) 7–14.
[11] B. De Pauw, T.J. Walsh, J.P. Donnelly, D.A. Stevens, J.E. Edwards, T. Calandra, et al., Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections coop-erative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group, Clin. Infect. Dis. 46 (2008) 1813–1821.
[12] D.W. Denning, Invasive aspergillosis, Clin. Infect. Dis. 26 (1998) 781–803.